The renal monoamine oxidases: pathophysiology and targets for therapeutic intervention.
The mitochondrial enzyme monoamine oxidases A and B are among the major metabolic agents for the degradation of the biogenic amines adrenaline, noradrenaline, dopamine and serotonin. The fact that the kidney contains a large amount of monoamine oxidase suggests that the renal effects of biogenic amines might depend in part on the activity of these enzymes.
Pizzinat
N
N
INSERM U388, Department of Renal Molecular Pharmacology and Physiology, University Hospital Centre, Rangueil, Toulouse, France.
Remaury
A
A
Parini
A
A
D000818:Animals; D006801:Humans; D007668:Kidney / Q000201:enzymology*; D007674:Kidney Diseases / Q000201:enzymology* / Q000503:physiopathology* / Q000628:therapy; D008995:Monoamine Oxidase / Q000096:biosynthesis / Q000378:metabolism*
D008995:Monoamine Oxidase